Algipharma

AlgiPharma is a Norwegian clinical-stage biotech leveraging its proprietary alginate oligosaccharide (OligoG) technology to address unmet needs in respiratory diseases and infections. Its platform serves as a drug delivery vehicle for various molecule types and as a standalone therapeutic targeting mucus clearance, biofilm disruption, and antibiotic resistance. With six completed clinical trials demonstrating safety in over 175 individuals and multiple formulation routes in development, the company is positioned to advance treatments for chronic conditions like cystic fibrosis and COPD.

Proprietary alginate oligosaccharide (OligoG) technology used as a standalone API for biofilm disruption and mucus modulation, and as a versatile drug delivery platform for various molecule types.

In CF, competition includes Vertex's CFTR modulators and other mucus-altering agents. In COPD, the landscape is crowded with inhalers and biologics. AlgiPharma's differentiation lies in its unique biofilm-disrupting mechanism, which addresses a root cause of infection not directly targeted by most competitors.